The COVID-19 pandemic disrupted the delivery and receipt of routine preventive services, including cancer screenings.¹ A systematic review and meta-analysis found an overall decrease of 46.7% for breast, 51.8% for cervical, and 44.9% for colorectal cancer screening tests performed from January to October of 2020.² More recent studies reported a potential rebound in screening for colorectal, breast, cervical, and prostate cancer in the summer of 2020.^3-9 However, these findings are not generalizable to the overall US population because they are based on claims databases, electronic medical records, or non-nationwide data. On the basis of the Center for Disease Control and Prevention's (CDC) Behavioral Risk Factor Surveillance System, a state-specific population-based database, we reported 6%-11% declines in past-year breast and cervical cancer screening prevalence in 2020, the first year of the COVID-19 pandemic.^10,11 The CDC also conducts the National Health Interview Survey (NHIS), which is a true, national survey of the US population.¹² Herein, we examine changes in the receipt of screening for breast, cervical, prostate, and colon and rectum cancer during the second year of the COVID-19 pandemic overall and by sociodemographic characteristics using the 2019 and 2021 NHIS.¹²